Top Banner
Heart Institute of the Caribbean (HIC) CARDIAC RISK EVALUATION: Searching for the vulnerable patient
37

Cardiac risk evaluation

Apr 13, 2017

Download

Health & Medicine

FELIX NUNURA
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Cardiac risk evaluation

Heart Institute of the Caribbean (HIC)

CARDIAC RISK EVALUATION:Searching for the vulnerable

patient

Page 2: Cardiac risk evaluation

Screening for the Risk Factors for the disease

Screening for the

disease

The Disease: Atheroesclerosis

Page 3: Cardiac risk evaluation

Types of Cardiovascular Disease

Page 4: Cardiac risk evaluation

What do you think about this patient ?

23 points, 22 % CV Risk

Page 5: Cardiac risk evaluation

What do you think about this patient..?

18 points, > 30 % CV Risk

Page 6: Cardiac risk evaluation

The risk of develop CV disease ( CHD or Stroke) in the next 10 years in percent (%) can be calculated

with the help of the Framingham Risk Score

Gender, Age, Total-C , HDL-C, SBP, Smoking status

Page 7: Cardiac risk evaluation

Systematic COronary Risk Evaluation (SCORE): based on gender, age, total cholesterol, systolic blood pressure and smoking status.

Roques F, Michel P, Goldstone AR, Nashef SA. The logistic EuroSCORE. Eur Heart J. 2003 May;24(9):882-3

Page 8: Cardiac risk evaluation

Effects of any treatment (to lower cholesterol / lower blood pressure) that reduced the risk of CVD in 50 %

100ptes

With20%CV

Risk 20

80

Treatment10

80

10

Will develop CHD or Stroke in the next 10 years

Will not develop CHD or Stroke in the next 10 years

Page 9: Cardiac risk evaluation

1994 4S 2002 PROSPER 1995 WOSCOPS 2002 ALLHAT-LLA 1996 CARE 2002 ASCOT-LLA 1998 AFCAPS/TEXCAPS 2004 PROVE-IT 1998 LIPID 2004 A to Z 2001 MIRACL 2005 TNT 2002 HPS 2005 IDEAL

2008 JUPITER

Study populations:Primary prevention

Acute coronary syndromes (Secondary prevention)Chronic Coronary heart disease (Secondary prevention)

*Trials with clinical outcomes

HMG-CoA Reductase Inhibitor:STATINSHMG-CoA Reductase Inhibitor:STATINSChronological Order of Event Driven Chronological Order of Event Driven

TrialsTrials

Page 10: Cardiac risk evaluation

Efficacy of antihypertensive treatmentEfficacy of antihypertensive treatment: Duration and homogeneity of the efficacy of antihypertensive drugs are currently quantified by computation of the smoothness index (SI) from ambulatory blood

pressure monitoring (ABPM) recordings.

The smoothness index (SI) identifies the occurrence of a balanced 24 h

blood pressure reduction with treatment and correlates with the

favourable effects of treatment on left ventricular hypertrophy better than the commonly used trough : peak

ratio.

According to the standard definition, the SI is calculated as the ratio

between the mean hourly reductions and the standard deviation of these

reductions. (American Journal of Hypertension 2005; 18, 24A )

Page 11: Cardiac risk evaluation

What do you think about this patient ?

Lifetime Risk50 %

Page 12: Cardiac risk evaluation

What do you think about this patient ?

Lifetime Risk69 %

Page 13: Cardiac risk evaluation

Future CV Risk Prediction: Concept of Lifetime Risk

Lloyd-Jones et al. Circulation 2006; 113: 791-798

Framingham Heart Study: Optimization of RFs in asymptomatic 50 year-olds associated with low lifetime CVD risk

OptimalTotal chol <180BP <120/80NonsmokerNon diabetic

Not optimalTotal chol 180-200BP 120-140/80-90

Elevated RFTotal chol 200-240SBP 140-160/90-100

Major RFTotal chol >240BP >160/90SmokerDiabetic

Page 14: Cardiac risk evaluation

Other issues:Low

H D L

Diabetes

Metabolic Syndrome

Inflammation

HsCRP

Triglycerides

Stress

Page 15: Cardiac risk evaluation

The “Super-Sizing” of America

“This year, Americans will spend more money on fast food than on higher education…”

Eric Schlosser. Eric Schlosser. Fast Food Nation: The Dark Side of the All-American MealFast Food Nation: The Dark Side of the All-American Meal..Harper Collins. 2002.Harper Collins. 2002.

Page 16: Cardiac risk evaluation

Haffner SM, Lehto S, Ronnemaa T, et al: N Engl J Med 339:229–234, 1998

Diabetes is a “cardiovascular disease risk equivalent”

Page 17: Cardiac risk evaluation
Page 18: Cardiac risk evaluation

Systemic inflammation

Eur Heart J 2010 (31) 3: 290-297

Page 19: Cardiac risk evaluation

Current Opinion 2012; 142:w13502

Page 20: Cardiac risk evaluation

Ps: Psychosocial stress as a risk factor

Page 21: Cardiac risk evaluation

Many times the traditional risk factor based screening fails in identifying the Vulnerable Patient.

-

Page 22: Cardiac risk evaluation

Sir Winston Churchill, 91 Sir Winston Churchill, 91 Jim Fixx, 53Jim Fixx, 53 Who Has More Cardiovascular Risk Who Has More Cardiovascular Risk

Factors?Factors?

Page 23: Cardiac risk evaluation

Existing Guidelines (Status Quo):• Screen for Risk Factors of Atherosclerosis• Treat Risk Factors of Atherosclerosis

Goal of “ new” Guidelines:• Screen for Atherosclerosis (the Disease)

regardless of, Risk Factors• Treat based on the Severity of the Disease

and its Risk Factors

ATHEROESCLEROSIS: Risk Factor screen Vs the disease

screen

Page 24: Cardiac risk evaluation

Slide 24

Atherosclerosis begins early :Usefulness and Prognostic Implications of Surrogate Markers

in Atherosclerosis

Risk factors

Surrogatemarkers

Arterial vascular symptoms

Clinical events (MI,

suddendeath)

Autopsy

LateEarly

Adapted from Crouse JR III. J Lipid Res. 2006;47:1677–1699; Nissen S. Am J Cardiol. 2001;87(suppl):15A–20A.

Page 25: Cardiac risk evaluation

Importance of Subclinical Disease Detection

• Atherosclerosis begins early• can be detected prior to a cardiac event

• Most MI’s -previously <40% stenosis • plaque rupture and thrombus (blood clot)!

• Stress tests only detects flow-limiting stenoses (blockages)

• Subclinical disease measures • target patients for “aggressive primary prevention”

Page 26: Cardiac risk evaluation
Page 27: Cardiac risk evaluation

Evaluating coronary vasoreactivity

Eur. Heart J 2010 (31) 7, 777-783

Page 28: Cardiac risk evaluation

012345678

<0.5 0.5-1.0

1.0-2.0

2.0-3.0

3.0-4.0

4.0-5.0

5.0-10.0

10.0-20.0

>20.0

Crude RRs Risks Adjusted for FRS

RR

of f

utur

e C

ardi

o. E

vent

s

Low risk Mod. risk High risk

hsCRPmg/L

Ridker PM, et al. Circulation 2004;109:1955-9.

Higher CRP levels predict increased risk for heart disease

Page 29: Cardiac risk evaluation
Page 30: Cardiac risk evaluation

From: Coronary Artery Calcium Scanning Should be Used for Primary Prevention: Title and subTitle BreakPros J Am Coll Cardiol Img. 2012;5(1):111-118. doi:10.1016/j.jcmg.2011.11.007

Page 31: Cardiac risk evaluation

Coronary Artery CalciumCoronary Artery Calcium

No CalcificationNo Calcification Severe Severe CalcificationCalcification

Left Main

LAD

LCX

AortaAorta

LALA

PAPA

Left Main

LAD

Measurement of CAC may be reasonable for cardiovascular risk assessment persons at low to intermediate risk (6% to 10% 10-year

risk).

Page 32: Cardiac risk evaluation

Direct in vivo measurement of thickness of carotid artery wall by B-mode ultrasound – “arterial biopsy”Vessel wall thickness correlates with status of atherosclerosis and cardiovascular events

Atherosclerosis is a systemic disorderDisease in carotid artery is predictive of disease in other vascular beds

Measurement of CA IMT

Adapted from Crouse JR III. J Lipid Res. 2006;47:1677–1699; Espeland MA, et al. Curr Controll Trials Cardiovasc Med. 2005;6:3; Kastelein JJP, et al. Am Heart J. 2005;149:234–239. .

Page 33: Cardiac risk evaluation

A well-established marker of atherosclerotic disease

CA IMT Measured by B-Mode Ultrasound

Page 34: Cardiac risk evaluation

Slide 34

Rotterdam StudyCA IMT Strongly Predictive of MI

*Adjusted for age and genderAdapted from van der Meer I, et al. Circulation. 2004;109:1089–1094.

1

1.682.05

2.91

0

1

2

3

<0.88 0.88–<0.99 0.99–<1.12 ≥1.12

CA IMT, mm

Haz

ard

Rat

io*

(n=1277) (n=1279) (n=1287) (n=1273)

Page 35: Cardiac risk evaluation

Current: “Sick care” to “Health care”

Page 36: Cardiac risk evaluation

Systematic COronary Risk Evaluation (SCORE): based on gender, age, total cholesterol, systolic blood pressure and smoking status.

Roques F, Michel P, Goldstone AR, Nashef SA. The logistic EuroSCORE. Eur Heart J. 2003 May;24(9):882-3

Page 37: Cardiac risk evaluation